Nephrology, Hypertension and Transplantation Medicine
Weill Cornell Medicine's nephrology program — in partnership with NewYork-Presbyterian, the #8 hospital in the country and the top hospital in New York 17 years running — is currently ranked #4 in the nation by U.S. News & World Report.
Our excellence is the fruit of a philosophy that a synergistic relationship between Nephrology and Hypertension, Pediatric Nephrology, Transplantation Medicine, Surgery and Pathology, Rogosin Institute and Nephrology services at Memorial Sloan Kettering Cancer Center, is essential for creating new patient advances that improve outcomes and educate the next generation of physicians and physician-scientists.
Our nephrology, transplantation, and hypertension specialists, all conveniently located in New York City’s Upper East Side, provide compassionate, comprehensive and state-of-the-art care to every patient afflicted with kidney disease, high blood pressure, requiring a kidney or pancreas transplant, or having previously undergone transplantation. We aim to provide optimal and individualized care for patients with these problems. To this end, our nephrologists provide renal consultation, renal biopsy, as well as evaluation and management of hypertension and other kidney disorders. Our hypertension specialists believe hypertension is not the same disease in every patient, and that it has different mechanisms in different individuals. Our transplant physicians provide all aspects of transplant medicine care. Each patient is treated based on his/her individual profile, with every attempt made to personalize care.
Nephrology, Hypertension and Transplantation Medicine Physicians
Specialized renal, hypertension and transplant medicine services include:
Kidney transplantation and pancreas transplantation medical services for patients with End-Stage Renal Disease (ESRD), and ESRD due to diabetes or type 1 diabetes.
Acute and chronic hemodialysis and peritoneal dialysis, hemoperfusion, hemofiltration, management of drug overdose, apheresis, and evaluation of fluid, electrolyte, acid-base and mineral metabolism disorders.
Biochemical and hormonal testing, electrocardiogram, 24-hour blood pressure monitoring, 24-hour ECG monitoring, stress testing, vascular testing, endocrine screening, non-drug therapy, home blood pressure instruction, nutrition counseling and the opportunity to participate in trials of new blood pressure medications.
Pediatric nephrologists who provide care and management for children with various kidney diseases including nephrotic syndrome, End-Stage Renal Disease, urinary tract infections, enuresis/wetting disorders, and others. We also offer management of hemodialysis and peritoneal dialysis for children with End-Stage Renal Disease as well as care and follow-up for children who require kidney transplantation.
Ranked #4 among more than 4500 hospitals evaluated in the 2017-2018 U.S. News & World Best Hospitals Report, our center offers world-class clinical services to patients with complex kidney diseases and disorders of blood pressure and circulation. Our goal is to provide optimal, individualized treatment for each patient.
The division provides evidence-based clinical care for patients afflicted with acute or chronic kidney disease; renal consultations and state-of-the-art renal replacement therapies (acute dialysis, chronic dialysis, and continuous renal replacement therapy) are provided by renal attending physicians.
Our center has a long and distinguished history in kidney transplantation. Our transplant nephrologists specialize in all aspects of kidney disorders and manage patients before and after kidney transplantation. For information on kidney transplantation, please visit http://weillcornell.org/transmed.
The Division of Pediatric Nephrology provides care and management for children with various kidney diseases, including nephrotic syndrome, urinary tract infections, vesicoureteral reflux, hematuria, proteinuria, hypertension, electrolyte disorders, complications of kidney stones and enuresis (bed-wetting) disorders.
We also offer management of hemodialysis and peritoneal dialysis for children with end stage renal disease.
The Transplant Program at NewYork-Presbyterian Hospital, led by physicians of Weill Cornell and Columbia, is a national leader in kidney and pancreas transplantation and has been ranked number 1 in the USA for the last ten years.
The NYPH/Weill Cornell Transplant Program is one of the largest programs in the country and the oldest transplant program in the New York metropolitan area. We have performed more than 4,500 transplants since the program’s inception in 1963. The program is renowned for:
maximizing transplant opportunities
delivering exceptional outcomes for patients through cutting-edge laboratory research
advanced surgical techniques
personalized medical management
national kidney exchanges
a multidisciplinary treatment approach
With more than 200 transplants performed per year at NewYork-Presbyterian/Weill Cornell Medical Center, our patient and graft survival rates continue to be stellar. The survival rate of kidney graft recipients is 97% and the graft survival rate is 95%, 1 year following transplantation. The program is a national leader in living kidney donation and kidney paired donation. Our world-renowned laboratory is at the forefront of translational research in transplantation and was the first to develop a gene expression-based test to noninvasively predict and prevent organ rejection after kidney transplantation. In addition, the pancreas transplant program offers expertise in transplantation for patients with life-threatening complication of type 1 diabetes mellitus. It is the only center in the New York tri-state region to have performed successful human islet cell transplantation, a minimally invasive procedure to isolate the cells in the pancreas that produce insulin, and implant them in a patient in order to improve, control, and reduce complications of type 1 diabetes.
Through the years, several innovations have been introduced in the transplantation arena: blood type (ABO) incompatible transplant; positive cross-match transplant; minimization of the amount of drugs patients need for successful transplantation; development of treatment protocols to reduce serious post-transplant complications (i.e., infection and malignancy); and, significantly, the development of noninvasive molecular assays for assessing transplant status, reducing the need for an invasive biopsy procedure.